<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792659</url>
  </required_header>
  <id_info>
    <org_study_id>1602017284</org_study_id>
    <nct_id>NCT03792659</nct_id>
  </id_info>
  <brief_title>The EXPLORE MG Registry for Myasthenia Gravis</brief_title>
  <official_title>Exploring Outcomes and Characteristics of Myasthenia Gravis: The EXPLORE MG Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create a Yale University Department of Neurology Myasthenia
      Gravis (MG) registry that will be used for current and future research projects involving the
      study of Myasthenia Gravis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will allow for the research of several mechanisms of Myasthenia Gravis (MG) by
      studying peripheral blood, stool, disease status and course, and treatment of subjects with
      MG. The EXPLORE-MG Registry focuses on varied aspects of MG such as disease management,
      health care utilization, health costs, disease characteristics, and diagnostic tools. As
      such, it will aid in a broader understanding of MG, while providing a registry from which
      questions about the disease may be better answered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>8 Years</target_duration>
  <primary_outcome>
    <measure>The number of successful blood draws will be reported at the conclusion of the sample collection</measure>
    <time_frame>8 years</time_frame>
    <description>Successful Collection of Blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of stool samples collected will be reported at the conclusion of the sample</measure>
    <time_frame>8 years</time_frame>
    <description>Count of Stool Samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Neurological Outpatients</arm_group_label>
    <description>Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample Draw</intervention_name>
    <description>Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.</description>
    <arm_group_label>Neurological Outpatients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      100 cc (less than 1/2 cup) of blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be 18 years of age or older with a clinical diagnosis of a Myasthenia Gravis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients diagnosed with Myasthenia Gravis presenting to the Yale Department of
             Neurology for clinical care or research interventions will be invited to donate their
             biological specimens/clinical data.

        Exclusion Criteria:

          -  Failure to meet the Inclusion Criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Nowak, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bailey Munro Sheldoon, PhD</last_name>
    <phone>203-737-7095</phone>
    <email>bailey.munrosheldon@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailey Munro Sheldon, PhD</last_name>
      <phone>203-737-7095</phone>
      <email>bailey.munrosheldon@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Nowak, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

